Dermatology Products · LP-090
Clotrimazole Cream
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-090Dermatology Products
- Generic identity
- ClotrimazoleCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-090
- Generic ingredient
- Clotrimazole
- Dosage form
- Cream
- Proposed strength
- 1%
- Proposed pack
- Tube 20 g / 30 g
- Portfolio category
- Dermatology Products
About Clotrimazole
Clotrimazole is an imidazole antifungal used in appropriate topical formulations for selected fungal infections. A skin cream has different instructions from vaginal, oral or other clotrimazole products. The affected site and diagnosis determine the relevant formulation. This ingredient-level educational profile does not establish Luang Pharma approved indications, certify effectiveness against every rash or confirm a particular cream base or preservative composition.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
A clinician or pharmacist should distinguish fungal infection from eczema, bacterial disease or another cause of redness and itching. Location, recurrence, immune status and the extent of disease influence whether a topical cream is appropriate. Persistent symptoms, scalp or nail involvement, or widespread disease may need a different assessment. Hygiene measures can be part of care, but symptom improvement alone does not establish that the original diagnosis was correct.
Important safety considerations
Local burning, stinging, redness or irritation may occur. Worsening rash or swelling can represent allergy and requires review. Keep a skin formulation away from the eyes and do not assume it is authorized for internal use. Pregnancy or breastfeeding questions should be considered in relation to the application site and actual label. Some formulations may affect barrier contraceptive materials; only the specific product information can confirm this. Persistent or worsening symptoms require reassessment.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue identifies a skin cream. The cream base, preservatives, excipients and suitability for particular sites require confirmation from product information. A concentration does not establish equivalence to a vaginal, oral, ophthalmic or injectable preparation containing the same ingredient. Authorized application instructions remain product-specific.
Keep the tube or container labeled, close it after use and avoid contaminating the contents. Follow the actual label for application sites, storage and expiry. Do not transfer another product’s instructions on dressings, sensitive areas or duration to this proposed presentation.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Clotrimazole
- Dosage form / presentation
- Cream
- Catalogue strength
- 1%
- Catalogue pack
- Tube 20 g / 30 g
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Skin cream and vaginal products not conflated. Barrier-contraceptive compatibility depends on the actual formulation.
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: Clotrimazolepublic-health medicine reference
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-090, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-090.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.